|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
93 581 | 80 916 | 82 209 | 73 031 | 76 967 | - |
| Entreprise Value (EV)1 |
119 535 | 78 449 | 82 450 | 103 910 | 94 505 | 87 086 |
| P/E ratio |
20,4x | 15,0x | 15,4x | 583x | 11,3x | 11,5x |
| Yield |
2,90% | 3,65% | 3,88% | 4,67% | 4,60% | 4,71% |
| Capitalization / Revenue |
3,58x | 3,66x | 3,66x | 2,96x | 3,10x | 3,23x |
| EV / Revenue |
4,58x | 3,55x | 3,67x | 4,21x | 3,80x | 3,66x |
| EV / EBITDA |
6,90x | 6,11x | 6,61x | 7,74x | 7,30x | 7,76x |
| Price to Book |
4,57x | 3,75x | 3,65x | 4,04x | 3,30x | 3,03x |
| Nbr of stocks (in thousands) |
1 306 269 | 1 293 620 | 1 265 146 | 1 253 528 | 1 253 528 | - |
| Reference price (USD) |
71,6 | 62,6 | 65,0 | 58,3 | 61,4 | 61,4 |
| Last update |
02/06/2018 | 02/04/2019 | 02/04/2020 | 02/04/2021 | 02/11/2021 | 02/11/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
26 107 | 22 127 | 22 449 | 24 689 | 24 857 | 23 802 |
| EBITDA1 |
17 317 | 12 840 | 12 468 | 13 142 | 12 953 | 11 218 |
| Operating profit (EBIT)1 |
16 031 | 11 411 | 11 064 | 11 704 | 12 388 | 11 305 |
| Operating Margin |
61,4% | 51,6% | 49,3% | 47,4% | 49,8% | 47,5% |
| Pre-Tax Profit (EBT)1 |
13 529 | 7 799 | 5 160 | 1 669 | 9 086 | 8 445 |
| Net income1 |
4 628 | 5 455 | 5 386 | 123 | 7 236 | 6 758 |
| Net margin |
17,7% | 24,7% | 24,0% | 0,50% | 29,1% | 28,4% |
| EPS2 |
3,51 | 4,17 | 4,22 | 0,10 | 5,41 | 5,32 |
| Dividend per Share2 |
2,08 | 2,28 | 2,52 | 2,72 | 2,82 | 2,89 |
| Last update |
02/06/2018 | 02/04/2019 | 02/04/2020 | 02/04/2021 | 02/15/2021 | 02/15/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
25 954 | - | 241 | 30 879 | 17 538 | 10 119 |
| Net Cash position1 |
- | 2 467 | - | - | - | - |
| Leverage (Debt / EBITDA) |
1,50x | -0,19x | 0,02x | 1,89x | 1,35x | 0,90x |
| Free Cash Flow1 |
11 308 | 7 476 | 8 319 | 7 411 | 9 672 | 9 259 |
| ROE (Net Profit / Equities) |
58,5% | 41,5% | 38,3% | 43,8% | 27,5% | 26,9% |
| Shareholders' equity1 |
7 915 | 13 136 | 14 055 | 281 | 26 305 | 25 138 |
| ROA (Net Profit / Asset) |
18,3% | 8,14% | 8,60% | 0,19% | 11,5% | 10,4% |
| Assets1 |
25 269 | 66 979 | 62 651 | 65 079 | 63 133 | 64 698 |
| Book Value Per Share2 |
15,7 | 16,7 | 17,8 | 14,4 | 18,6 | 20,3 |
| Cash Flow per Share2 |
9,02 | 6,42 | 7,16 | 6,09 | 6,62 | 6,01 |
| Capex1 |
590 | 924 | 825 | 768 | 754 | 747 |
| Capex / Sales |
2,26% | 4,18% | 3,67% | 3,14% | 3,03% | 3,14% |
| Last update |
02/06/2018 | 02/04/2019 | 02/04/2020 | 02/04/2021 | 02/19/2021 | 02/19/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Gilead Sciences : raises 2020 profit forecast on remdesivir strength |
Capitalization (USD) 76 966 628 348 Net sales (USD) 22 449 000 000 Number of employees 11 800 Sales / Employee (USD) 1 902 458 Free-Float capitalization (USD) 76 694 441 545 Avg. Exchange 20 sessions (USD) 540 583 151 Average Daily Capital Traded 0,70%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
